A randomised controlled intervention trial evaluating the efficacy of an Australianised Mediterranean diet compared to the habitual Australian diet on cognitive function, psychological wellbeing and cardiovascular health in healthy older adults (MedLey study): protocol paper by unknown
STUDY PROTOCOL Open Access
A randomised controlled intervention trial
evaluating the efficacy of an Australianised
Mediterranean diet compared to the
habitual Australian diet on cognitive
function, psychological wellbeing and
cardiovascular health in healthy older
adults (MedLey study): protocol paper
Courtney R. Davis1*, Janet Bryan2, Jonathan M. Hodgson3, Carlene Wilson4, Varinderpal Dhillon5
and Karen J. Murphy1
Abstract
Background: The Mediterranean diet (MedDiet) is associated with considerable health benefits for cardiovascular and
cognitive health, particularly within the Mediterranean basin. Whether Australian populations will similarly benefit from
the MedDiet is unknown. We aim to assess the effects of a MedDiet on cognitive and cardiovascular health indicators
amongst the elderly (MedLey study). Here we describe in detail the protocol for the MedLey study.
Methods: Medley is a randomised, parallel controlled dietary intervention trial. Data collection occurred at the Sansom
Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia between 2013 and 2015.
Omnivorous men and women aged ≥65 years, who were non-smokers, had no previously diagnosed cardiovascular
disease, history of brain trauma, cognitive impairment, major disease or cancer were recruited from the general public
(n = 166). The intervention comprised an Australianised version of the traditional MedDiet characterised by small amounts
of red meat, processed deli meats and high sugar foods; moderate amounts of dairy and poultry; and a high plant food
content including abundant extra virgin olive oil. Volunteers were stratified by age, gender and body mass index (kg/m2)
to follow either their habitual diet (control condition) or the intervention MedDiet for 24 weeks. Primary outcome
measures included cognitive function, endothelial function, cerebrovascular flow, blood lipids, inflammatory markers,
fasting glucose and insulin, blood pressure, and body composition. Secondary outcomes included food cravings,
psychological wellbeing and DNA damage markers. These were assessed at baseline, 12 and 24 weeks. Dietary intakes
were assessed at baseline, two and four months to assess adherence to the prescribed diet. For main outcome
measures, groups will be compared over time using a linear mixed effects model, with Cohen’s d effect sizes.
Subgroup analysis based on adherence to the intervention, medications and alcohol consumption may be performed
in an exploratory fashion.
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Discussion: The MedLey study will provide evidence as to whether dietary changes in line with an Australianised
MedDiet can benefit cognitive performance, endothelial function and other cardiovascular risk factors and
psychological wellbeing amongst older Australians. Results could inform formation of national dietary
guidelines and nutrition-related practices such as dietetics.
Trial registration: The trial was registered on the Australia New Zealand. Clinical Trials Register
(ACTRN12613000602729). Trial registration date: 27 May 2013.
Keywords: Mediterranean diet, Cognitive function, Cardiovascular health, Randomised trial, Australia
Background
Several observational studies have supported the Mediterra-
nean dietary pattern as a healthy diet that lowers risk of car-
diovascular disease (CVD) [1]. Cardiovascular diseases are
responsible for nearly one fifth of total deaths in Australia,
occurring mostly as coronary heart disease (myocardial in-
farction and angina) [2]. The precursor is atherosclerosis,
an inflammatory condition affecting the functional capacity
of the blood vessels [3, 4]. The exact mechanism(s) involved
in the development of atherosclerosis are still being under-
stood, however, the link between various lifestyle factors
such as smoking, physical activity and diet and the preva-
lence of CVD have been well established through epidemio-
logical studies [5, 6]. Those consuming a plant-based diet
(fruits, vegetables, nuts, seeds and vegetable oils) have a re-
duced risk of CVD [7]. The diets followed traditionally in
Mediterranean countries including Greece, Italy, Spain and
France include these components and have been repeatedly
linked to improvements in cardiovascular health indicators,
and reduced mortality rates from CVD [8–11]. A meta-
analysis of observational trials showed higher adherence to
the MedDiet reduces risk of CVD including coronary heart
disease and stroke, as well as overall mortality [1]. Recently,
the PREDIMED (Prevención con Dieta Mediterránea)
study, a large scale randomised controlled trial, reported
that this dietary pattern supplemented with extra virgin
olive oil or nuts, reduces the risk of major cardiovascular
events in individuals at high CVD risk [12]. The Mediterra-
nean diet (MedDiet) is also consistent with the Australian
Heart Foundation’s recommendations for a healthy diet,
that is high in fibre, omega-3 long chain fatty acids, plant
sterols, and low in saturated and trans fatty acids [13–15].
The effect of the MedDiet on cardiovascular biomarkers
and end-points has previously been tested in European
populations with positive outcomes [11, 12, 16]. However,
only one small (n = 20) randomised cross-over trial has
been conducted in Australia on markers of diabetes severity
[17]. With promising results in other countries, studies are
needed to determine if this dietary pattern is a viable op-
tion to improve markers of cardiometabolic health and
potentially reduce incident CVD in non-Mediterranean
populations like Australia. The following will describe
the methods for the Mediterranean diet for cognitive




We aim to determine the effects of an Australianised ver-
sion of the traditional MedDiet on cardiometabolic bio-
markers and cognitive performance. The secondary aim is
to determine how closely Australians can adhere to Medi-
terranean dietary practices with dietetic supervision. This
paper presents the protocol for the recruitment and ran-
domisation, study design, methods of dietary, cognitive
and cardiometabolic data collection and describes the
Australianised MedDiet and the measures of dietary com-
pliance used.
Recruitment and randomisation
Volunteers were recruited from metropolitan Adelaide,
South Australia, Australia. Exclusion criteria are shown
in Table 1. These criteria were assessed by a diet and
lifestyle questionnaire (DLQ) used to screen volunteers
expressing interest. If eligible based on the DLQ, volunteers
were screened at the Sansom Institute for Health Research
clinic (University of South Australia, Adelaide) for evidence
of cognitive decline (assessed by the DemTect screening
tool for the presence of dementia and mild cognitive im-
pairment) [18] and had their fasting blood lipids, glucose,
insulin, high sensitivity C-reactive protein (hs-CRP), liver
function and immune function assessed by a full blood
examination to detect health issues.
Additionally body mass, height and blood pressure were
measured to confirm eligibility. A rolling recruitment oc-
curred in two cohorts, the first from June to September
2013 and the second from March to May 2014. Seventy-
seven volunteers were enrolled for cohort one and 89 for
cohort two. The staggered-start method was used. A max-
imum of 10 volunteers were started per week for 12 weeks,
with an interval of three weeks to avoid scheduling visits
during the Christmas holiday period. Baseline data collec-
tion occurred between August and November 2013 for co-
hort one, and between May and August 2014 for cohort
two. Fourteen volunteers withdrew before commencement,
and baseline data was collected for 152 volunteers (Fig. 1).
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Volunteers were randomly allocated to either the ha-
bitual diet (HabDiet) control group or the MedDiet
intervention group stratified by gender, body mass index
(BMI) and age by the process of minimization [19]. An
honorarium payment of $100 was awarded to volunteers
who commenced the study on a pro rata basis to cover
parking and travel related expenses. The study was con-
ducted according to the guidelines laid down in the Dec-
laration of Helsinki and all procedures involving human
participants were approved by the Human Research Ethics
Committee (22 June 2013, #31163), University of South
Australia, Adelaide, Australia. Written informed consent
was obtained from all participants before commencement.
Study design
MedLey is a randomised, controlled dietary intervention
trial lasting 24 weeks, including six major and 10 minor
clinic visits all of which occurred at the Sansom Institute
for Health Research. Volunteers first attended two clinic
visits spaced 1 week apart during which primary and sec-
ondary outcome measures were assessed to obtain baseline
data (Fig. 2). Primary outcome measures included cogni-
tive function, endothelial function, cerebrovascular flow,
blood lipids, inflammatory markers, fasting glucose and in-
sulin, blood pressure, and body composition. Secondary
outcomes included food cravings, psychological wellbeing
and DNA damage markers. Additionally dietary intake was
assessed. These assessments are described in detail in fol-
lowing sections. Both baseline visits were conducted after
a minimum 8 h fast (water allowed). At the first clinic visit,
(Visit 1A), a 26 ml blood sample was collected to measure
blood lipids, glucose, insulin, hs-CRP, erythrocyte fatty
acids, F2-isoprostanes and carotenoids. A buccal cell, saliva
and 9 mL blood sample was also provided by a sub-sample
of participants not taking any medications, for assessment
of the ApoE4 genotype and DNA damage biomarkers
(telomere length, mitochondrial DNA deletions, DNA base
oxidation and micronucleus index). Blood pressure, trans
cranial Doppler (TCD), flow mediated dilatation (FMD)
and cognitive function was also assessed at Visit 1A. Dur-
ing the following six days volunteers collected a 24-hour
urine sample, completed a 3-day weighed food record
(WFR) and monitored their blood pressure. A series of
questionnaires to assess psychological wellbeing and a vali-
dated food frequency questionnaire (FFQ) were completed
[20, 21]. Volunteers were also administered a demographic
questionnaire, collecting information on country of birth,
marital, educational and work status and level of income.
Upon return to the clinic (Visit 1B) these questionnaires,
the blood pressure monitor and readings, urine sample
and 3-day WFR were returned. Height, body mass, waist
and hip circumference, bone mineral density and body
composition (by dual x-ray absorptiometry (DEXA) scan)
were assessed and the volunteers received their dietary in-
structions. Excluding the WFR, FFQ and demographic
questionnaire, these assessments were undertaken again
after 12 and 24 weeks (3 and 6 months). Totally, the study
period lasted 25 weeks (from week 0–1 between Vis-
it1A and Visit1B volunteers were not following their allo-
cated diets). Volunteers attended 10 minor clinic visits
Fig. 1 Consort flow diagram for recruitment, randomisation and
baseline data collection
Table 1 Exclusion criteria
• Person considered by the investigator to be unwilling, unlikely or
unable to comprehend or comply with the study protocol
• Age <65 years
• Previous/current traumatic head/brain injury, neurological or
psychiatric conditions
• Previous stroke
• Unstable use of anti–depressant medication (<6 months)
• Use of medication to treat anxiety
• Current or recent (in the last 6 months) malignancy
• Major liver, kidney, respiratory or gastrointestinal disease
• Current cardiovascular disease or angina
• Uncontrolled hypertension (>170/100)
• Current smoker
• Vegetarian (does not eat red meat, poultry or fish)
• Actively undertaking weight loss program
• Use of appetite suppressants or Orlistat (Xenical)
• Age and education adjusted scores of <13 on the DemTect
• Body mass >135 kg (limit on dual xray energy absorptiometry (DEXA)
scanner)
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fortnightly, each approximately 30 min. These visits en-
gaged volunteers with a dietitian to discuss the dietary
component of the trial, report changes in medications and
physical activity levels and any adverse events. A lifetime
diet questionnaire (LDQ) was administered during week
21 (cohort 1) or week 5 (cohort 2) to capture information
on eating habits throughout the lifespan [22]. A follow-up
FFQ and 3-day WFR were administered at week 11 and
week 19. These were completed during the fortnight and
returned at the subsequent appointment.
A protocol amendment occurred during baseline data
collection of cohort one. It was noted that volunteers
were commenting on their experiences with food crav-
ings. It was decided that the Food Cravings Inventory
(FCI) [23] should be administered at each time point to
formally capture changes related to food cravings. This
was altered in the protocol and included as an ethics
amendment. Therefore excluding withdrawals, 16 volun-
teers from cohort one and all volunteers from cohort
two (n = 74) completed the FCI at all visits. A further 10
volunteers completed the FCI at baseline and 6 months
in cohort one.
Assessments
Cognitive and psychological well-being assessments
The selected cognitive test battery was designed to assess
cognitive performance indicators sensitive to aging and
nutritional factors, based on published literature. The bat-
tery assessed verbal and spatial episodic memory, verbal
working memory, high order executive functions, attention
and speed of processing, and is described in detail in
Knight et al. [24]. Briefly, the cognitive test battery in-
cluded the following (in order of presentation to the par-
ticipants): D-KEFs Tower of London, the Rey Auditory
Verbal Learning Test, the WAIS IV Symbol Search and
the WAIS IV Coding, the Stroop test, the WAIS-IV digit
span forward, digit span backwards and letter-number se-
quencing, Initial Letter Fluency, Excluded Letter Fluency,
and the Benton Visual Retention Test. Alternate forms of
these tests were presented to individuals at each time point
in order to reduce practice effects. The sequence of alter-
native versions was randomly determined by a researcher
not involved in data collection. Alternate sequences were
counter-balanced across all visits. All cognitive testing took
place in the same private clinic room after an 8 h fast.
Wherever possible, the tests were administered at the
same time of day and by the same researcher at each visit.
Scoring of the test battery was completed by the same re-
searcher for all participants.
To assess psychological wellbeing, the following ques-
tionnaires were completed during the week between visit
A and visit B: the SF-36 Health Survey (version 2) [25],
the Self-evaluation Questionnaire (STAIP-AD test form
Y-1 and Y-2) [26], the Centre for Epidemiological Studies
Depression Scale (CES-D) (NIMH) [27], the Perceived
Stress Scale [28], and the Leeds Sleep Evaluation Ques-
tionnaire [29]. These assessments were completed again
at 3 and 6 months.
Cardiometabolic measures
Trans cranial Doppler
TCD is non-invasive measure of cerebrovascular respon-
siveness (CVR) in the middle cerebral artery (MCA) and
has been described elsewhere [24]. Briefly, participants
sat in a temperature-controlled room (22 °C) for at least
10 min prior to commencing the assessment. The trans-
temporal window was used as the acoustic window for
insonation of the MCA at a mean depth of 50 ± 10 mm.
Where possible, a clear signal for the left and right side
was obtained – when not possible, one side was still re-
corded and included in analysis. If neither left nor right-
side trans-temporal windows gave a clear signal, after
approximately 10 min of searching the test was aban-
doned and not repeated at subsequent visits. Participants
were fitted with a non-rebreathing two-way valve and
facemask encompassing nose and mouth (General Elec-
tric Logiq 5 Expert). A 30 s baseline clip was recorded
to establish normal flow velocity. The participant then
inhaled carbogen gas (5 % CO2/95 % O2) for 150 s to
initiate hypercapnia induced cerebrovascular dilatation.
Mean flow velocity in the MCA was recorded for each car-
diac cycle. To improve test reliability, this assessment was
repeated three times with a rest period of at least 2 min
between tests to allow flow velocity to return to baseline
Fig. 2 Assessments at each clinic visit
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levels. Analysis was performed using Systat Software Inc.
(San Jose, California, USA) and the peak increase in mean
flow velocity will be determined. CVR will be expressed as
a percentage change from baseline [(peak mean flow vel-
ocity – baseline mean flow velocity) * 100 /baseline mean
flow velocity].
Flow mediated dilatation
The primary cardiovascular health outcome measure of
MedLey is endothelial function, assessed by FMD of the
right-side brachial artery. FMD was measured using the
techniques described by Stout [30]. The volunteer was
positioned supine on an electronically height-adjustable
bed, in a temperature controlled room (22 °C). The bed
height was adjusted so that the volunteer’s right arm
could be extended horizontally on the same vertical
plane of the heart. The upper arm and hand rested on
pillows, with space around the forearm to allow for posi-
tioning and inflation of a blood pressure cuff. The cuff
was placed 2–3 cm below the antecubital fossa. The vol-
unteer was at rest for a minimum of 10 min before com-
mencement, and had abstained from all food and drink
(other than water) for a minimum of 8 h. A two-
dimensional B-mode 12 MHz transducer (General Elec-
tric Logiq 5 Expert) ultrasound probe was used at a
depth of 2 cm. The probe was placed 3–7 cm above the
antecubital fossa, after palpating for the location of the
brachial artery. Three five-second recordings, spaced at
least five seconds apart, were recorded before inflation
to determine baseline artery diameter (15 s in total). The
blood pressure cuff was then rapidly inflated to
200 mmHg to occlude blood flow for 5 min. A 5 s re-
cording was taken at 4:45 min to determine pre-
deflation diameter. At 5 min, the cuff was rapidly de-
flated and the images continuously recorded for three
minutes post deflation, in 15 s intervals. The electrocar-
diogram for all volunteers was recorded with all videos.
Analysis will be performed using the Vascular Tools for
Research software package, Brachial Analyser for Re-
search with DICOM module (Medical Imaging Assess-
ment, version 6.1.3).
As fewer participants were needed to meet power for
TCD and FMD than the total recruited, only participants
with high quality scans had TCD and FMD performed at
all time-points. To determine scan quality, a grading sys-
tem was developed by JH, CD, KM and JB. For FMD,
scores were based on the following criteria: number of
images recorded in full, visibility of the intima/media
layers in all clips, and extent of movement of the ultra-
sound probe, especially between baseline and post-
deflation recordings. Other considerations included par-
ticipant movement and discomfort. A similar scoring
system was utilised for TCD, criteria including poor sig-
nal strength, volunteer intolerance and movement and
poor image clarity. Where possible, all participants
underwent FMD and TCD at baseline, and each scan
was graded immediately by the operator from 1 to 5. A
grade of five reflected maximum quality. If the scans
were considered unsuitable due to any of the criteria not
being met, a rating of 3.5 or less was given. Only base-
line scans with ratings between 3.5 and five were re-
peated at subsequent visits. Complete TCD data was
obtained at three visits for 71 volunteers, and a further
15 had data from two visits. FMD scans were complete
for 96 volunteers at three visits, and a further six had
data for two scans. Independent samples t-tests were
used to determine whether there were any differences
between those with complete data and those without for
age, BMI, waist to hip ratio, body fat % and blood lipids
at baseline. For TCD, total cholesterol was significantly
higher amongst those without scan data (P < 0.05), and
for FMD total cholesterol and LDL cholesterol were sig-
nificantly higher amongst those without scan data (P <
0.01, respectively). Chi squared tests showed there was
no relationship between gender (P > 0.5) or diet alloca-
tion and whether TCD was performed (P > 0.5), and no
relationship between gender (P > 0.2) or diet allocation
and whether FMD was performed (P > 0.2) indicating
groups were even for gender and diet allocation.
Blood and urinary parameters
Trained staff used venepuncture to collect samples using
the Vacuette® blood tube collection system. Samples were
collected at clinic visit A at each time point for ana-
lysis of triglycerides, total cholesterol, low-density lipopro-
tein (LDL), high-density lipoprotein (HDL), and total
cholesterol to HDL ratio, glucose, insulin, hs-CRP, erythro-
cyte fatty acids (FAs), F2-isoprostanes and carotenoids.
After collection blood tubes were immediately placed on
ice and shielded from light. Lipids, glucose, insulin and hs-
CRP were analysed at a National Association of Testing
Authorities (NATA) accredited pathology centre within
two hours of collection.
Blood samples for the remaining measures were centri-
fuged at 4000 rpm for 10 min at 4 °C and stored at −80 °C
until analyses. Carotenoids, retinol and tocopherols were
measured from plasma according to the method of Barua
et al. [31] using high performance liquid chromatography.
Erythrocyte fatty acids were measured using direct trans-
esterification as described elsewhere [32].
Volunteers collected a 24 h urine sample for analysis
of 24-hour excretion of urinary magnesium, calcium, po-
tassium and sodium, to measure dietary adherence. Sam-
ple collection started after completion of the first void
on the morning before, and continued up to and includ-
ing the first void on the morning of the second clinic
visit (Visit B). Urinary metabolites (sodium, potassium,
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magnesium and calcium) were analysed at a NATA
accredited lab.
Assessment of DNA damage biomarkers and ApoE4
genotyping
For the assessment of DNA damage and ApoE4 genotyp-
ing, a sub-group of volunteers (n = 22) who were not
taking medication were selected. Data was collected at
baseline and visit 3A for 20 volunteers (eight males, 12
females, eight MedDiet, 12 HabDiet). For DNA isolation,
a 2 ml saliva sample was collected using the Oragene DNA
kit (OG-500, DNA Genotek), and a buccal cell sample was
provided. In the fasted state, volunteers rinsed their mouths
with water thoroughly then filled a 2 ml collection tube
with saliva. This was then immediately mixed with a stabil-
isation reagent and stored at room temperature until ana-
lysis. Volunteers used soft-bristled brushes to obtain buccal
cells from the left and right side cheek. After collection,
brushes were immediately washed in a stabilisation reagent
and stored at room temperature. ApoE4 genotyping was
performed using the TaqMan® SNP genotyping assay kit
(Applied Biosystems) as described by Koch et al. [33].
Cytokenesis-block micronucleus-cytome assay
A 9 ml blood sample was collected for the Cytokenesis-
block micronucleus-Cytome (CMBN-Cyt) assay [34].
Heparinised blood was collected and plasma separated
by centrifugation. Plasma was removed and lymphocytes
were isolated as described previously by Fenech et al.
[34]. The CBMN-Cyt assay is a validated measure of
chromosomal DNA damage, cytostasis, and cytotoxicity
[34]. The degree of chromosomal DNA damage can be
quantified by scoring the frequency of bi-nucleated cells
(cells with two nuclei) containing micronuclei, nucleo-
plasmic bridges, and nuclear buds. Cytostasis was deter-
mined by calculating the nuclear division index (NDI)
using ratios of viable cells with one, two, or more than
two nuclei whereas cytotoxicity was gauged by the rela-
tive ratio of dead (apoptotic or necrotic) to viable cells.
Cytostasis was determined by the NDI, calculated by
scoring the ratio of viable mono-nucleated, bi-nucleated,
and multi-nucleated (three or more nuclei) cells per 500
cells according to the following formula: NDI = (M1 +
2 M2 + 3 M3 + 4 M4)/T where T is total number of viable
cells scored). Cytotoxicity was determined via the num-
ber of apoptotic and necrotic cells scored per 500 cells,
whereas chromosomal DNA damage was measured by
scoring the number of micronuclei nucleoplasmic brid-
ges and nuclear buds per 1000 BN cells. The scoring cri-
teria are as previously described for lymphocytes [34].
Telomere length measurement
Both relative repeat copy number of telomere (T) and
single copy gene (36B4) (S) were determined using real-
time polymerase chain reaction (PCR) as described pre-
viously [35] with power SYBR green PCR master mix
using Applied Biosystems 7300 Real-Time PCR System
(Applied Biosystems, USA). Each sample was analysed in
triplicate both with telomere and 36B4 gene primers. To
perform standard curves with each gene, one reference
DNA was serially diluted with deionised water by 1.68
fold per dilution to create seven concentrations of DNA
ranging from 1.78 to 40 ng/μL. The R2 of the standard
curves were >98.5 %, and the amplification efficiency of
each pair of primers was >98.5 %. The relative telomere
length was expressed as the ratio of these two values (T/
S ratio), reflecting the average telomere repeat copy
number of each DNA sample calculated relative to refer-
ence DNA. To control for inter-assay variability, five
control DNA samples were also included in each PCR
run. We also used the absolute method as described pre-
viously [36] to calculate the actual telomere length in
base pair in each individual.
Anthropometry and body composition
Height and body mass were measured to calculate BMI
(kg/m2). Height was measured to the nearest 0.1 cm whilst
barefoot using a wall-mounted stadiometer (SECA; Vogel
and Halke, Hamburg, Germany). Body mass was measured
to the nearest 0.1 kg with participants wearing a light hos-
pital gown, using the TANITA Ultimate Scale 2000 (Tanita
Corporation, Tokyo, Japan) after an eight hour fast. In
cases where body mass could not be measured in a gown,
volunteers were asked to remove shoes, heavy jewellery
and outer layers of clothing and empty pockets. Body mass
was also measured fortnightly at approximately the same
time of day, without shoes and after removal of pocket
contents and outer layers of clothing. Waist and hip mea-
surements were taken using a Luftkin Executive Thin line
2 m metal measuring tape according ISAK international
guidelines, as described by Norton and Olds [37]. Two
measures of waist and hip circumference were taken to
the nearest 0.1 cm, and the average calculated. If the two
measures differed by 2 % or more a third measure was
taken and the average of all three measures calculated.
Waist circumference was measured directly over skin or
over a thin layer of clothing. In cases where a narrowing of
the waist was visible and lay between the tenth rib and top
of the iliac crest, visual narrow was used. In cases where
there was no visual narrowing, the mid-point between the
tenth rib and the top of the iliac crest was used. Either
mid-point or visual narrowing was used at all subsequent
visits. Hip circumference was measured over the hospital
gown or underwear, at the point of greatest protrusion of
the gluteal. Waist to hip ratio was calculated by dividing
waist circumference (cm) into hip circumference (cm).
Participants had their percentage of body fat, fat mass
(kg), abdominal fat (g) and lean mass (% and kg) assessed
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using DEXA (Lunar Prodigy, General Electric, Madison,
WI, USA) scans after an eight hour fast. Volunteers were
required to void their bladder, remove shoes, outer cloth-
ing and jewellery, watches, glasses, and hearing aids. If it
was not possible to remove all jewellery, any worn at base-
line was also worn at subsequent scans. Wearing a hos-
pital gown and underwear, the volunteer was instructed to
lie supine on the DEXA bed, with palms flat and arms
straightened by the sides. In cases where the hands were
outside the scan area, volunteers were asked to place
palms against thighs. Abdominal fat content was gener-
ated using Lunar Prodigy software from regional analysis
of the DEXA scan to assess the region from the top of the
iliac crest, with the lateral borders extending to the edge
of the abdominal soft tissue, and the upper margin 20 %
above the pelvis between the pelvis and the neck borders.
Blood pressure
Blood pressure was assessed in clinic using an OMRON
Healthcare Co. digital blood pressure monitor (model
1A1B (Hem-7000-CIL). Volunteers were seated for 10 min,
were asked to remove outer layers of clothing and/or roll
up sleeves, and place feet flat on the ground. The forearm
rested at table height, palm up, and the cuff was placed ap-
proximately 2–3 cm above the anti-cubital fossa. Three
measurements of blood pressure were taken, each spaced
at least one minute apart. Systolic and diastolic blood pres-
sure and pulse were recorded. Volunteers were then pro-
vided with an A&D Company ltd. digital blood pressure
monitor (model UA-767), with detailed instructions to
monitor their own blood pressure at home. Blood pressure
was taken on six consecutive days, morning (prior to food
or beverage consumption), during the afternoon and even-
ing (before bed). At each time-point three readings of sys-
tolic, diastolic blood pressure and heart rate were recorded,
each spaced at least one minute apart. Volunteers were
instructed to avoid caffeine for 60 min and exercise for
30 min prior to taking the measurements.
The Australianised Mediterranean intervention diet and
measures of compliance
Development of the Australianised Mediterranean diet
The MedLey diet was based on a literature review to deter-
mine the amounts of key foods and nutritional content of
the MedDiet (unpublished work, Davis et al. 2015). Briefly,
the review aimed to determine an average food and nutri-
ent content, according to observations of Mediterranean
populations and MedDiets used in previous intervention
trials . Food content (in grams) was based on an average of
15 different MedDiets, and nutrient content on eight. The
MedLey diet was modelled on these findings.
A recommendation for servings of 13 food groups was
calculated based on the average gram content determined
from the literature review. Serving sizes were based on
current Australian guidelines, with several exceptions (eggs,
wine, extra virgin olive oil (EVOO) and fish) [38]. A 7-day
menu was then developed meeting the required numbers
of servings per day and per week. The servings for fruits,
nuts and dairy products had to be separately determined as
they were not presented as isolated food groups in the lit-
erature review. Reports of traditional MedDiet intakes such
as that in of the Cretan population reported in Kromhout
et al. [39] were consulted as well as Mediterranean diet pyr-
amids to determine an appropriate number of servings
fruit, nuts, milk, cheese and yoghurt. The traditional Cretan
diet included approximately 450 g fruit/day, not including
nuts. For this reason the fruit recommendation was set at
three 150 g servings per day. The recommendation for nuts
was based on the Mediterranean diet foundation pyramid
which suggests nuts/seeds should be consumed daily [40].
According to the literature review dairy foods comprised
no more than one serve per day; however the Mediterra-
nean diet foundation pyramid and reports of the traditional
Cretan diet suggest a greater dairy consumption. Addition-
ally, the Australian Nutrient Reference Values indicate the
Estimated Average Requirement for calcium is 840–
1100 mg/day for an older population [41]. For these rea-
sons it was deemed appropriate to increase the dairy con-
tent to 2–3 serves/day. To maintain the ratio of saturated
to monounsaturated fatty acids skim milk and reduced fat
yoghurt was strongly encouraged over full-fat versions. The
final menu contained a standard number of servings for
EVOO, vegetables, fruits, legumes, potatoes, wholegrain
breads and cereal products, red wine, potatoes, yoghurt,
fish, nuts, red meat and poultry.
The menu was entered into the dietary analysis software
package FoodWorks Professional (Version 7.0.3016, Xyris
Software Australia) to determine the nutrient content.
This was compared with the nutrient content derived
from the literature review. In cases where the nutrient
content of the MedLey diet differed vastly from the aver-
age, key Mediterranean diet pyramids and papers outlin-
ing traditional intakes were consulted to ensure the diet
reflected a traditional MedDiet. For example, fibre intake
was averaged at 33 g/day in the literature review; however
the total fibre was 47 g/day based on the menu, which is
similar to traditional diets [39].
Because the traditional MedDiet is relatively high in
energy (9300 kJ compared to average estimated require-
ment of 8700 kJ), to account for lower energy require-
ments in the Australian population two lower energy
versions of the diet were created. This was achieved by
reducing the total numbers of servings of EVOO, vegeta-
bles, grain products, nuts, fruits, meats and extra foods.
Energy levels 2 and 3 contained the same nutrients per
1000 kJ ± 5 % as the model diet (Energy level 1). The
MedLey diet was then piloted over two weeks amongst
10 men and women aged ≥65 years (Davis et al. under
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review). Several changes to the diet were introduced based
on feedback from the pilot study including the creation of
a 4th energy level (6400 kJ/day), the addition of recom-
mendations for eggs, milk, smallgoods and extra (discre-
tionary) foods, the introduction of flavoured Greek yoghurt
as an alternative to plain, and a reduced recommendation
for poultry. The MedLey diet menu was adjusted to in-
corporate these recommendations (Table 2). Either a mini-
mum or maximum recommendation was given for each
food group, with the exception of yoghurt and poultry
where either exact requirements or a range was provided.
For energy levels two and four ranges rather than min-
imums were also provided for fruit and EVOO to help con-
trol energy intake. Table 3 shows the nutrient content of
each energy level.
Measures of dietary intake
Volunteers completed a 3-day WFR and FFQ at baseline,
2 and 4 months. Before completing the WFR, volunteers
were instructed by trained personnel to include details
of foods and beverages such as type (e.g., whether low-
fat or full-fat), quantity (e.g., weight on packages, weight
in grams, metric cup or spoon measures, or units of
foods), method of preparation (e.g., fat trimmed, grilled,
eaten raw), brand name and recipes of composite home-
cooked foods. All foods and beverages consumed in a
consecutive 3-day period consisting of two week days
and one weekend day were recorded. Volunteers were
provided with digital kitchen scales to assist in accur-
ately recording quantity. Clarification of any points of
confusion was untaken by trained personnel at the time
when the WFR was returned. FoodWorks Professional
(Version 7.0.3016, Xyris Software Australia) was used to
calculate nutrient and food intakes from WFRs. Volun-
teers were administered with the Cancer Council Victoria
74-item dietary questionnaire, validated for fruit and vege-
table intake [21]. This was supplemented with additional
questions regarding intake of soft drink, fish, nuts and oil.
Volunteers were instructed to answer the baseline ques-
tionnaire based on the previous 12 months and the two
and four month questionnaires on the previous two
months only. Returned FFQs were checked for errors and
accuracy with the volunteer.
Administration of the Mediterranean diet and resources
Volunteers were informed of their diet allocation at visit
1B by a study dietitian. All study dietitians were trained by
the chief dietitian in administration of the MedLey diet
and HabDiet and were observed in their first 2–3 sessions
with volunteers to ensure consistency in the delivery of
the instructions. Volunteers commenced the diet the fol-
lowing day, and maintained this for the following 24 weeks.
Table 2 Recommended number of servings on the MedLey diet by energy level
Energy level 1 Energy level 2 Energy level 3 Energy level 4
9600 kJ/2300 kcal 8600 kJ/2055 kcal 7400 kJ/1770 kcal 6400 kJ/1500 kcal
Foods (serving sizea) Daily servings
Extra virgin olive oil (1 Tbsp.) ≥3 2–3 ≥2 1–2
Vegetables (75 g) ≥6 ≥5 ≥5 ≥5
Fruits (150 g) ≥3 2–3 ≥2 ≥2
Cereal products (30–120 g) ≥6 ≥5 ≥4 ≥4
Milk (250 ml) ≤1 ≤1 ≤1 ≤1
Red wine (150 ml) ≤2 ≤2 ≤2 ≤2
Potato (white only) (1 medium) ≤1 ≤1 ≤1 ≤1
Weekly servings
Yoghurt (170 g) 6 6 6 6
Cheese (40 g) ≤4 ≤4 ≤4 ≤3
Nuts (35 g) ≥6 ≥5 ≥5 ≥4
Legumes (75 g) ≥3 ≥3 ≥3 ≥2
Fish (150 g) ≥3 ≥3 ≥3 ≥2
Poultry (100 g) 1–3 1–3 1–3 1–3
Red meat (100 g) ≤1 ≤1 ≤1 ≤1
Small goods (50 g) ≤2 ≤2 ≤2 ≤1
Eggs (1 egg) ≤6 ≤5 ≤4 ≤4
Extras (discretionary foods) (600 kJ) ≤3 ≤3 ≤3 ≤2
aServing sizes were loosely based on the Australian Guide to Healthy Eating standard serves, and were modified to increase similarity of the total food amounts to
the MedDiet while retaining simplicity of the recommended numbers of serves for volunteers
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For the HabDiet group instructions were to maintain
current dietary intake, physical activity, dietary supple-
ments and medications for the duration of the study, un-
less instructed otherwise by a medical professional.
Volunteers were informed that normal seasonal and occa-
sional variations in diet were acceptable, and to avoid
major changes such as introducing a new food or ceasing
any regularly consumed food/s while on the study. The
HabDiet volunteers were originally offered foods similar
to those being provided to the MedDiet group (canola oil,
yoghurt, bread and milk) to provide approximately 30 %
of estimated energy requirements per fortnight. The can-
ola oil was kindly donated by Goodman Fielder Ltd. How-
ever, it was essential to avoid altering the diets of those
randomised to the HabDiet. Due to the wide range of
foods preferred by volunteers in the HabDiet, within the
first fortnight it was deemed impractical to provide foods
they usually consumed. Instead, we offered a $10 (AUD)
shopping voucher per fortnight for the volunteers preferred
supermarket, allowing them to purchase up to 30 % of
their estimated energy requirements. This was amended in
the protocol and approved by the ethics committee. Volun-
teers in cohort 1 continued to be offered foods in place of
the voucher, however all accepted vouchers after the first
fortnight. Volunteers in cohort 2 were not offered foods.
For volunteers on the MedLey diet, the instructions
were given verbally with the aid of written resources
which the volunteers kept for future reference. The edu-
cation sessions lasted between 45 min and 1 h. The vol-
unteer first selected a day to represent a ‘typical’ day
from their 3-day WFR completed the previous week.
This was then entered into FoodWorks Professional by
the dietitian aided by the volunteer to ensure accuracy.
The energy intake calculated was then used to guide
which of the four energy levels (9.6 MJ, 8.6 MJ, 7.4 MJ
or 6.4 MJ/day) of the MedLey diet was selected for the
volunteer. Following this, volunteers had a short intro-
duction to the fundamental principles of the MedDiet.
Advice for recipe modification and eating out was given
and volunteers received a recipe book. Volunteers were
then presented with the serving sizes for each food
group and given a table to indicate how many servings
of key foods they had to consume, based on which en-
ergy level they were assigned (Table 2). Volunteers were
encouraged to ask questions, such that the sessions were
interactive. Finally, the daily checklists were provided
and discussed to ensure the volunteer was competent at
filling them out correctly. Volunteers were provided with
Greek yoghurt, unsalted mixed nuts (peanuts, almonds,
and walnuts), canned legumes, canned tuna and EVOO
to last one fortnight. The amounts of these foods and
their energy contributions for each energy level are
shown in Table 4.
Volunteers purchased and prepared all other foods,
and could consume the necessary servings at any time
and in any way which suited them. Volunteers were
instructed to maintain their current physical activity,
dietary supplements and medications for the duration of
Table 3 Daily nutrient content of the Australianised Mediterranean









Energy (kJ/kcal) 9608/2300 8593/2055 7387/1770 6384/1500
Protein (g) 97 90 79 64
Total fat (g) 105 93 79 66
- SFA (g) 20 18 15 11
- PUFA (g) 20 16 14 13
- MUFA (g) 58 53 44 37
Cholesterol (mg) 90 83 80 66
CHO (g) 209 186 158 146
Sugars (g) 100 86 78 73
Alcohol (g) 6 5 5 5
Dietary fibre (g) 47 40 35 32
Vitamin C (mg) 291.8 254.9 251.5 219.7
Vitamin E (mg) 22.9 21.5 17.8 16.0
Total folate (μg) 529.9 454.7 440.4 391.7
β-carotene
equivalents (μg)
6141.9 5528.5 4988.6 4602.5
Sodium (mg) 1887.8 1653.3 1315.5 1057.9
Potassium (mg) 4324.5 3916.0 3574.0 3092.2
Magnesium (mg) 451.8 408.1 354.0 306.7
Calcium (mg) 841.3 783.9 652.4 571.2
Phosphorus (mg) 1732.3 1594.3 1386.0 1137.9
Iron (mg) 18.6 17.0 13.6 11.9
Zinc (mg) 11.9 10.8 9.3 7.5
kJ from protein (%) 17 18 18 17
kJ from fat (%) 40 40 40 38
kJ from SFA (%) 8 8 8 7
kJ from MUFA (%) 22 23 22 21
kJ from CHO (%) 39 39 39 41
Fat as MUFA (%) 59 61 60 61
Fat as PUFA (%) 20 18 19 21
Fat as SFA (%) 21 21 21 19
Long chain n-3 (EPA
+ DHA + DPA) (mg)
1051 1045 1042 566
18:2n-6 linoleic
acid (g)
16.94 13.32 12.19 11.17
18:3n-3 linolenic
(ALA) (g)
1.78 1.38 1.08 1.11
SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA
polyunsaturated fatty acid, CHO carbohydrate, n-3 omega-3, EPA
eicosapentaenoic acid, DHA docosahexaenoic acid, DPA docosapentaenoic
acid, ALA alpha-linolenic acid
aVersion 7.0.3016, Xyris Software Australia
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the study, unless instructed otherwise by a medical
professional.
Measures of compliance to the Mediterranean diet
Compliance to the two study diets (MedLey and HabDiet)
was monitored by measuring erythrocyte FAs (particularly
MUFA:SFA), plasma carotenoids, urinary metabolites, FFQs
and 3-day WFR’s. Volunteers following the MedLey diet
were also required to complete daily checklists to indicate
they had consumed the required numbers of servings of
foods. The foods listed on the checklist included EVOO,
vegetables, fruits, wholemeal grain products, skim milk, po-
tato, red wine, yoghurt, cheese, fish, nuts, legumes, red
meat, poultry, smallgoods, eggs and extra foods (discretion-
ary foods), for which there were recommended numbers of
daily or weekly servings. Volunteers were instructed in de-
tail by a trained dietitian to mark the checklist to indicate
when one full serving was consumed. If more or less was
consumed, volunteers were instructed to indicate this
clearly. The volunteers returned the checklists every fort-
night and these were discussed with a study dietitian to
clarify serving sizes and address any issues or problems
with compliance. Those following their habitual diets did
not complete daily checklists.
Power calculations
A systematic review by Norman et al. [42] identified 38
studies which resulted in 62 effect sizes. For all but six
studies the minimally important difference for health-
related quality of life instruments was close to one half a
standard deviation (mean = 0.495). Based on this effect
size, we calculate that 128 subjects (two groups of n = 64)
will provide 80 % power to detect a significant (P < 0.05)
0.5 SD difference in change in cognitive outcomes. A 0.5
SD improvement in cognitive outcomes is both clinically
relevant and socially relevant as it would represent an
annual cost saving of approximately $28 million. An add-
itional 38 volunteers (19 per group, total n = 166) will be
recruited to account for a 30 % subject withdrawal rate.
Generally the Sansom Research Institute has a less than
20 % withdrawal rate. For FMD and TCD we calculate
that 32 participants would give 80 % power to detect a sta-
tistically significant (P < 0.05) 40 % improvement, with an
effect size of one in either FMD or CVR. A flow diagram
of subjects’ progress through the trial will be provided in
accordance with the CONSORT statement.
Statistics
Descriptive statistics will be provided for the MedDiet
and HabDiet groups for baseline characteristics, includ-
ing clinical, sociodemographic and dietary information.
For continuous variables, means and SD are provided. For
categorical variables, counts and percentages are provided.
To assess differences between groups in cognitive function
and cardiovascular outcomes, a linear mixed effects model
will be fitted. Non-normally distributed variables will be
log transformed before analysis. Covariates will be deter-
mined using a correlation matrix to identify significant in-
teractions between potential confounders. Outcomes will
be adjusted for energy intake. An unadjusted and adjusted
model will be presented. The unadjusted model will in-
clude age, gender and BMI where significant. The adjusted
model will include these parameters as well as any poten-
tial confounders found to be correlated to outcomes which
may include energy intake, demographic variables, physical
activity, and psychological variables. We will analyse on an
intention to treat basis. To assess effect size Cohen’s d will
be calculated. Subgroup analyses adjusting for dietary com-
pliance, medication use and alcohol consumption may be
performed in an exploratory capacity. Statistical signifi-
cance will be set at P ≤ 0.05, and analysis will be performed
using SPSS for Windows (version 20.0; SPSS, Chicago, IL).
Table 4 Foods provided to the Mediterranean diet group each fortnight and energy contribution to total
% energy contribution to total fortnightly energy
Foods Amount provided
per fortnight
Energy level 1 (134,512 kJ) Energy level 2 (120,302 kJ) Energy level 3 (103,418 kJ) Energy level 4 (89,376 kJ)
Legumesa 450 g net weight 1.5 1.6 1.8 2.0
Tunab 190 g net weight 0.6 0.7 0.8 0.9
Nutsc Approximately 350 g 8.1 7.6 7.0 8.1
Olive oild 750 ml 18.9 17.6 16.4 14.2
Yoghurte 2.04 kg 5.1 5.7 6.6 7.7
Total % energy provided 34 33 33 33
aEdgell (Simplot Australia Pty Ltd) brown lentils, chickpeas and 4-bean mix canned in brine. Average between three presented
bJohn West (Simplot Australia Pty Ltd) plain, sweet chilli, lemon pepper and tomato onion in spring water
cUnsalted, raw nuts. Equal weights of peanuts, almonds and walnuts. Energy level 1 received 420 g, energy level 2 350 g and levels 3 and 4 received 280 g
per fortnight
dCobram Estate© extra virgin olive oil, medium strength flavour. Volunteers received their daily quota as 750 ml bottles (1 per fortnight), to provide 3 Tbsp/day.
Thus energy levels 2, 3 and 4 did not use the whole quantity each fortnight
eChobani© no fat plain, no fat flavours and 2 % fat flavours provided. Volunteers were given 12 tubs weighing 170 g each per fortnight, and received an even mix
of each type unless otherwise specified. An average of the three types is shown here
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Discussion
The MedLey study is designed to assess the effects of an
Australianised MedDiet on cognitive function and cardio-
vascular health indicators over 6 months in a healthy
population of older adults. This paper outlines the proto-
col for the collection of cardiometabolic and cognitive
data, the design and administration of the MedLey diet
and measurements of compliance.
So far no randomised trials in Australia have investi-
gated any effect of the MedDiet on cardiometabolic risk
factors for CVD without weight loss. The Medi-RIVAGE
study was a 3 month randomised trial conducted in France
comparing the effects of a modernised MedDiet with the
low-fat diet recommended by the American Heart Associ-
ation on clinical and biochemical risk factors for CVD
[16]. Total and LDL cholesterol, triglycerides and glucose
decreased in both groups, with a tendency for greater de-
creases in the MedDiet group (no significant differences
between groups observed). However both groups lost >1
BMI point, whereas we aim to maintain weight at baseline
levels. Other randomised trials have investigated the im-
pact of the MedDiet on cardiovascular health outcomes;
the Lyon Diet heart study was conducted with secondary
CVD patients in France [11], and the Prevencíon con dieta
Mediterránea study was conducted in high-risk partici-
pants free of disease in Spain [12]. The results of both tri-
als showed benefits of the MedDiet to the populations
studied, for prevention of stroke, secondary myocardial in-
farction and improved lipid profiles. Indeed a review of ex-
perimental studies investigating the MedDiet suggested
the diet improves endothelial function and the lipid profile,
but the only Australian study included in the review was a
weight loss study [43]. Geographical and methodological
differences in study design and recruitment limit the ap-
plicability of such findings to an Australian population.
Whether these benefits would occur in an Australian
population without weight loss is likely but unknown.
The secondary aim of the MedLey trial is to deter-
mine whether Australians can follow the MedDiet.
Good adherence with the MedDiet underpins essen-
tially any health benefits achieved – if for any number
of cultural, genetic, environmental or other reasons the
MedDiet was unacceptable in Australia, it would not be
a useful intervention. One small study (n = 27) amongst
Australian-born adults with Type 2 diabetes gave par-
ticipants a traditional MedDiet for 12 weeks, and vol-
unteers achieved high compliance to the diet [17].
However almost all (minimum of 70 %) of the diet was
provided as pre-prepared foods. We piloted the Med-
Diet used in MedLey in a small group of elderly adults
and found good adherence over a fortnight, and good
general acceptance of the diet (Davis et al. 2015 under
review), which was indicative that it could be adhered
to over a longer period.
The collection of cardiometabolic and dietary data over
6 months in MedLey should provide information as to
whether Australians can follow the MedDiet and whether
there will be similar health benefits as seen in other coun-
tries. Future publications will detail major outcomes from
MedLey and add understanding to whether the MedDiet
should be promoted in Australia.




CVD: Cardiovascular disease; MedDiet: Mediterranean diet; MedLey: Mediterranean
diet for cognitive and cardiovascular health in the elderly; DLQ: Diet and lifestyle
questionnaire; hs-CRP: High sensitivity C-reactive protein; HabDiet: Habitual diet;
BMI: Body mass index; TCD: Trans cranial Doppler; FMD: Flow mediated dilatation;
WFR: Weighed food record; FFQ: Food frequency questionnaire; DEXA: Dual x-ray
absorptiometry; LDQ: Lifetime diet questionnaire; FCI: Food craving inventory;
CVR: Cerebrovascular responsiveness; MCA: Middle cerebral artery;
LDL: Low-density lipoprotein; HDL: High density lipoprotein; FAs: Fatty
acids; NATA: National association of testing authorities; CMBN-Cyt: Cytokenesis-
block micronucleus-Cytome; NDI: Nuclear division index; PCR: Polymerase chain
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